• Merck & Co. Inc., of Whitehouse Station, N.J., reported data from the two-month discontinuation phase of its 12-month study showing that patients who stopped taking insomnia drug suvorexant, following daily use for one year, experienced a return of their sleeping difficulties similar to those who received placebo, while adverse events were generally consistent with those reported during the 12-month study.